

# Pharmacy Program Quarterly Update – Changes Effective Oct. 1, 2022 – Part 1

#### **Table of Contents**

- October 1 Drug List Revisions (Higher Tier Changes)
- October 1 Drug List Exclusions (Drugs No Longer Covered)
- Dispensing Limit Changes
- Utilization Management (Prior Authorization) Program Changes
- Other Pharmacy Program Updates/Reminders
  - Change in Benefit Coverage for Select High Cost Products
  - Updates to the Member Pay the Difference (MPTD) Program
  - Split Fill Program Category Expansion
  - o BCBSOK Change for Maintenance Indicator
  - o BCBSOK Increase in Mail Order Multiplier

**UPDATE:** As a reminder, the Quarterly Pharmacy Changes awareness article has been separated into a Part 1 and Part 2 article. This part 1 article includes changes that require member notification – drug list revisions/exclusions, dispensing limits, utilization management changes and general information on pharmacy benefit program updates. Our intention is to alert you of these changes as our members are receiving letters on changes to their drug list and/or pharmacy benefit. The part 2 article will be published closer to the October 1 effective date.

# **Drug List Changes**

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) will be made to the Blue Cross and Blue Shield of Oklahoma (BCBSOK) drug lists, effective Oct. 1, 2022. Changes by drug list are listed on the charts below.

Drug List Updates (Revisions/Exclusions) - As of Oct. 1, 2022

Non-Preferred Brand <sup>1</sup>	Drug Class/ Condition Used	Preferred Generic Alternative(s) <sup>2</sup>	Preferred Brand Alternative(s) <sup>1, 2</sup>
	For		
Basic, Multi-Tier Bas	sic, Enhanced and	<b>Multi-Tier Enhanced Drug</b>	Lists Revisions
CYSTADANE (betaine	Homocystinuria	There is a generic equivalent	ent available. Please talk
powder for oral solution)		to your doctor or pharmac	ist about other
		medication(s) available for your condition.	
VIMPAT (lacosamide tab 50	Seizures	There is a generic equivalent available. Please talk	
mg, 100 mg, 150 mg, 200,		to your doctor or pharmacist about other	
mg)		medication(s) available for your condition.	
Multi-Tier Basic and Multi-Tier Enhanced Drug Lists Revisions			
DEXAMETHASONE	Inflammatory	methylprednisolone	
(dexamethasone tab 0.5 mg,	Conditions	tablets, prednisone	
0.75 mg)		tablets	

Drug <sup>1</sup>	Drug Class/ Condition Used For	Generic Alternatives <sup>1,2</sup>	Brand Alternatives <sup>1,2</sup>
		ormance Select Drug Lists	Revisions
DEXAMETHASONE	Inflammatory	methylprednisolone	
(dexamethasone tab 0.5 mg,	Conditions	tablets, prednisone	
0.75 mg)		tablets	
MORPHINE SULFATE	Pain	morphine sulfate	
(morphine sulfate oral soln		solution 10 mg/5 ml	
20 mg/5 ml)			
MORPHINE SULFATE ER	Pain	Please talk to your doctor	
(morphine sulfate cap er		medication(s) available for	your condition.
24hr 10 mg, 20 mg, 30 mg,			
50 mg, 60 mg, 80 mg, 100			
mg)			
QUINIDINE SULFATE	Arrhythmia	Please talk to your doctor	
(quinidine sulfate tab 200		medication(s) available for	your condition.
mg, 300 mg)			
SULFADIAZINE	Infections	Please talk to your doctor	
(sulfadiazine tab 500 mg)	<b>D</b> .	medication(s) available for	
TRAMADOL HCL ER	Pain	Please talk to your doctor	•
(tramadol hcl tab er 24hr		medication(s) available for	your condition.
biphasic release 100 mg,			
200 mg, 300 mg)	D 11 1	5, , , , , , , , , , , , , , , , , , ,	
TRIHEXYPHENIDYL HCL	Parkinson's	Please talk to your doctor or pharmacist about other	
(trihexyphenidyl hcl oral soln	Disease,	medication(s) available for	your condition.
0.4 mg/ml)	Extrapyramidal		
VANDAZOLE	Disorders Bacterial	motronidazola vaginal	
		metronidazole vaginal	
(metronidazole vaginal gel 0.75%)	Vaginosis	gel 0.75%	
0.7376)			
Ralance	ad and Porformano	e Select Drug Lists Revis	ions
MOXIFLOXACIN	Antibacterial-	ciprofloxacin ophthalmic	
HYDROCHLORIDE	Ophthalmic	solution, gatifloxacin	
(moxifloxacin hcl ophth soln	Opridianiio	ophthalmic solution,	
0.5% (base eq) (2 times		ofloxacin ophthalmic	
daily))		solution, moxifloxacin	
		ophthalmic solution	
	1	1 -printentillo obtation	
	Balanced Dri	ug List Revisions	
ZOLPIDEM TARTRATE	Insomnia	eszopiclone tablets,	
(zolpidem tartrate sl tab 1.75		zaleplon capsules,	
mg, 3.5 mg)		zolpidem tablets	
V. V.			
Health Insurance Marketplace (HIM) Drug List Revisions			ions
DEXAMETHASONE -	Inflammatory	methylprednisolone	
dexamethasone tab 0.5 mg,	Conditions	tablets, prednisone	
0.75 mg		tablets	
MORPHINE SULFATE -	Pain	morphine sulfate	
morphine sulfate oral soln 20		solution 10 mg/5 ml	
mg/5 ml			

QUINIDINE SULFATE -	Arrhythmia	Please talk to your doctor or pharmacist about other	25
	Airriyumna	Please talk to your doctor or pharmacist about other	
quinidine sulfate tab 200 mg,		medication(s) available for your condition.	
300 mg	Infactions		
SULFADIAZINE -	Infections	Please talk to your doctor or pharmacist about other	
sulfadiazine tab 500 mg	D 11 1	medication(s) available for your condition.	
TRIHEXYPHENIDYL HCL	Parkinson's	Please talk to your doctor or pharmacist about other	
(trihexyphenidyl hcl oral soln	Disease,	medication(s) available for your condition.	
0.4 mg/ml)	Extrapyramidal		
	Disorders		
		rmance Select Drug Lists Exclusions	
BIDIL (isosorbide dinitrate-	Heart Failure	There is a generic equivalent available. Please talk	(
hydralazine hcl tab 20-37.5		to your doctor or pharmacist about other	
mg)		medication(s) available for your condition.	
CONTRAVE (naltrexone	Weight Loss	Qsymia, Saxenda,	
hcl-bupropion hcl tab er 12hr		Wegovy	
8-90 mg)			
ESBRIET (pirfenidone tab	Idiopathic	There is a generic equivalent available. Please talk	(
267 mg, 801 mg)	Pulmonary	to your doctor or pharmacist about other	
	Fibrosis	medication(s) available for your condition.	
FERRIPROX (deferiprone	Transfusional	There is a generic equivalent available. Please talk	(
tab 1000 mg) `	Iron Overload	to your doctor or pharmacist about other	
J 3,		medication(s) available for your condition.	
K-PHOS (potassium	Urinary	There is a generic equivalent available. Please talk	
phosphate monobasic tab	Acidification	to your doctor or pharmacist about other	
500 mg)	7 10.0	medication(s) available for your condition.	
SAMSCA (tolvaptan tab 15	Hyponatremia	There is a generic equivalent available. Please talk	(
mg)	1 Typoriationia	to your doctor or pharmacist about other	`
9/		medication(s) available for your condition.	
STALEVO 50 (carbidopa-	Parkinson's	There is a generic equivalent available. Please talk	_
levodopa-entacapone tabs	Disease	to your doctor or pharmacist about other	`
12.5-50-200 mg)	Discase	medication(s) available for your condition.	
STALEVO 75 (carbidopa-	Parkinson's	There is a generic equivalent available. Please talk	_
levodopa-entacapone tabs	Disease	to your doctor or pharmacist about other	١.
18.75-75-200 mg)	Disease	medication(s) available for your condition.	
STALEVO 100 (carbidopa-	Parkinson's	There is a generic equivalent available. Please talk	_
levodopa-entacapone tabs	Disease	to your doctor or pharmacist about other	١.
25-100-200 mg)	Disease	medication(s) available for your condition.	
STALEVO 125 (carbidopa-	Parkinson's	There is a generic equivalent available. Please talk	
levodopa-entacapone tabs		to your doctor or pharmacist about other	١.
31.25-125-200 mg)	Disease	•	
	Parkinson's	medication(s) available for your condition.	
STALEVO 150 (carbidopa-		There is a generic equivalent available. Please talk	•
levodopa-entacapone tabs	Disease	to your doctor or pharmacist about other	
37.5-150-200 mg)	D. d	medication(s) available for your condition.	
STALEVO 200 (carbidopa-	Parkinson's	There is a generic equivalent available. Please talk	(
levodopa-entacapone tabs	Disease	to your doctor or pharmacist about other	
50-200-200 mg)	0	medication(s) available for your condition.	
UKONIQ (umbralisib	Cancer	Please talk to your doctor or pharmacist about othe	<del>)</del> r
tosylate tab 200 mg)		medication(s) available for your condition.	=
VIMPAT (lacosamide tab 50	Seizures	There is a generic equivalent available. Please talk	(
mg,100 mg, 150 mg, 200		to your doctor or pharmacist about other	
mg)		medication(s) available for your condition.	

Darfarma	and Parformer	aco Soloct Drug Lieto Evel	ucione
metronidazole lotion 0.75%	Rosacea	nce Select Drug Lists Excl metronidazole cream	usions
metromazore lottom 0.7570	Nosacca	0.75%, metronidazole	
		gel 0.75%	
testosterone td gel 20.25	Hypogonadism	testosterone gel pump	
mg/1.25 gm (1.62%), 40.5	l Typogoriaaioni	1.62%	
mg/2.5 gm (1.62%)			
tretinoin gel 0.025%	Acne	tretinoin cream 0.025%	
		ug List Exclusions	
ACZONE (dapsone gel	Acne	There is a generic equival	
7.5%)		to your doctor or pharmac	
		medication(s) available for	
COMBIGAN (brimonidine	Glaucoma,	There is a generic equival	
tartrate-timolol maleate	Ocular	to your doctor or pharmac	
ophth soln 0.2-0.5%)	Hypertension	medication(s) available for	
ZIPSOR (diclofenac	Pain/	There is a generic equival	
potassium cap 25 mg)	Inflammation	to your doctor or pharmac	
		medication(s) available for	r your condition.
	Porformance Sole	ct Drug List Exclusions	
adapalene-benzoyl peroxide	Acne	tretinoin cream 0.1%	
gel 0.3-2.5%	Aono	treumont cream 6.170	
90.0.0 2.070			
Health Ir	nsurance Marketpl	ace (HIM) Drug List Exclu	sions
COMBIGAN - brimonidine	Glaucoma,	There is a generic equival	
tartrate-timolol maleate	Ocular	to your doctor or pharmac	
ophth soln 0.2-0.5%	Hypertension	medication(s) available for	
ESBRIET - pirfenidone tab	Idiopathic	There is a generic equival	ent available. Please talk
267 mg, 801 mg	Pulmonary	to your doctor or pharmac	ist about other
	Fibrosis	medication(s) available for	
FERRIPROX - deferiprone	Iron Overload	There is a generic equival	
tab 1000 mg		to your doctor or pharmac	
		medication(s) available for	
K-PHOS - potassium	Hypophosphate	There is a generic equival	
phosphate monobasic tab	mia	to your doctor or pharmac	
500 mg		medication(s) available for	
SAMSCA - tolvaptan tab 15	Hyponatremia	There is a generic equival	
mg		to your doctor or pharmac	
		medication(s) available for	r your condition.
testosterone td gel 20.25	Hypogonadism	testosterone gel pump	
mg/1.25 gm (1.62%), 40.5		1.62%	
mg/2.5 gm (1.62%)	0	Diagram to Had	
Ukoniq - umbralisib tosylate	Cancer		or pharmacist about other
tab 200 mg	Coizuras	medication(s) available for	•
VIMPAT - lacosamide oral	Seizures	There is a generic equival	
solution 10 mg/mL		to your doctor or pharmac	
VIMPAT - lacosamide tab 50	Seizures	medication(s) available for There is a generic equival	
mg, 100 mg, 150 mg, 200	OCIZUI 68	to your doctor or pharmac	
mg		medication(s) available for	
mg		Triculculon(s) available 10	i your condition.

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner. <sup>2</sup>This list is not all inclusive. Other medicines may be available in this drug class.

## **Dispensing Limit Changes**

BCBSOK's prescription drug benefit program includes coverage limits on certain medications and drug categories. Dispensing limits are based on U.S. Food and Drug Administration (FDA) approved dosage regimens and product labeling. Changes by drug list are listed on the charts below.

BCBSOK letters all members with a claim for a drug included in the Dispensing Limit Program, regardless of the prescribed dosage. This means members may receive a letter even though their prescribed dosage doesn't meet or exceed the dispensing limit.

#### Effective June 15, 2022:

Drug Class and Medication(s) <sup>1</sup>	Dispensing Limit(s)	
2021 Health Insurance Marketplace (HIM), 2022 HIM, Performance and Performance Select		
Drug Lists		
Oxbryta		
Oxbryta (voxelotor)* 90 tablets per 30 days		

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner.

# Effective Sept. 1, 2022:

Drug Class and Medication(s) <sup>1</sup>	Dispensing Limit(s)	
2021 Health Insurance Marketplace (HIM), 2022 HIM, Balanced, Performance and		
Performance Select Drug Lists		
IL-13 Antagonist		
Adbry (tralokinumab-ldrm)* 4 mL per 30 days		

# Effective Oct. 1, 2022:

Drug Class and Medication(s) <sup>1</sup>	Dispensing Limit(s)		
Basic, Enhanced, 2022 Health Insurance Marketplace (HIM), Balanced, Performance and			
Performance Select Drug Lists			
Alternative Dosage Form			
Dartisla ODT*	120 tablets per 30 days		
Lyvispah (baclofen) 5 mg Granule packet*2	120 packets per 30 days		
Lyvispah (baclofen) 10 mg Granule packet*2	120 packets per 30 days		
Lyvispah (baclofen) 20 mg Granule packet*2	120 packets per 30 days		
Valsartan oral solution*	2400 mL per 30 days		
Miscellaneous			
Emla (lidocaine-prilocaine) 2.5%-2.5%	60 grams per 30 days		
Therapeutic Alternatives			
METAXALONE TAB 400 MG*	240 tablets per 30 days		
PHOSPHOLINE SOL 0.125%OP*	5 mL per 30 days		
Basic, Enhanced, 2021 HIM, 2022 HIM, Bala	nced, Performance and Performance Select		
Drug	Lists		
Cibinqo			
Cibinqo (abrocitinib) 50 mg tablets*	30 tablets per 30 days		
Cibinqo (abrocitinib) 100 mg tablets*	30 tablets per 30 days		
Cibinqo (abrocitinib) 200 mg tablets*	30 tablets per 30 days		
Insulin Pumps			
Omnipod DASH kit/Omnipod 5 kit*	1 kit per 720 days		

<sup>\*</sup> Not all members may have been notified due to limited utilization.

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner.

\* Not all members may have been notified due to limited utilization.

Pyrukynd			
Pyrukynd (mitapivat) Therapy Pack 5 MG*	7 tablets per 365 days		
Pyrukynd (mitapivat) Therapy Pack 7 x 20 MG & 7	·		
x 5 MG <sup>*</sup>	·		
Pyrukynd (mitapivat) Therapy Pack 7 x 50 MG & 7	14 tablets per 365 days		
x 20 MG*			
Pyrukynd (mitapivat) 5 mg tablets*	56 tablets per 28 days		
Pyrukynd (mitapivat) 20 mg tablets*	56 tablets per 28 days		
Pyrukynd (mitapivat) 50 mg tablets*	56 tablets per 28 days		
Recorlev			
Recorlev (levoketoconazole)*	240 tablets per 30 days		
Tarpeyo			
ARPEYO (budesonide)* 120 capsules per 30 days			
Basic, Enhanced and Balanced Drug Lists			
Oxbryta			
Oxbryta (voxelotor)	90 tablets per 30 days		
Basic and Enhanced Drug Lists			
IL-13 Antagonist			
Adbry (tralokinumab-ldrm) 4 mL per 30 days			
Vuity			
Vuity (pilocarpine HCL) ophthalmic solution	2.5 mL per 30 days		

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner. \* Not all members may have been notified due to limited utilization.

# Clarification to the July 2022 Quarterly Changes Dispensing Limit Letter

The dispensing limit letter incorrectly listed Edarbi, Edarbyclor and Soolantra as target drugs included in the Therapeutic Alternatives program. These target drugs belong to the Miscellaneous program, effective July 1, 2022.

Letters mailed in late April to impacted members on the Basic, Enhanced, 2022 Health Insurance Marketplace (HIM), Balanced, Performance and Performance Select Drug Lists. Clarification letters will not be sent to members because the dispensing limits are accurate on the letter and both programs apply to the drug lists mentioned above.

## **Standard Utilization Management Program Package Changes**

#### **Prior Authorization (PA) Program Changes**

Several drug categories and/or targeted medications will be added to the PA programs for standard pharmacy benefit plans. This includes ASO groups that have selected auto updates. For groups that have not selected auto updates, these programs will be available for selection as of the program effective date. Contact your BCBSOK representative for more information.

# **New Target Drugs Added to Existing PA Programs**

Effective Oct. 1, 2022, the following changes will be applied:

- Target drugs Dartisla ODT, Valsartan oral solution and Lyvispah (baclofen) granule packet will be added to the Alternative Dosage Form PA program. This change applies to the 2022 Health Insurance Marketplace (HIM), Performance and Performance Select Drug Lists.\*
- Target drugs METAXALONE TAB 400 MG, PREDNISOLONE SOD PHOSPHATE ORAL SOLN 10 MG/5 ML (BASE EQUIV), PHOSPHOLINE SOL 0.125%OP, METFORMIN TAB 625 MG and

The target drug Lyvispah is misspelled on the dispensing limits letter for Basic and Enhanced Drug Lists.

VTAMA (tapinarof) 1% CREAM will be included in the Therapeutic Alternatives PA program. This change applies to the 2022 HIM Drug Lists.\*

Target drug Omnipod DASH kit/Omnipod 5 kit will be added to the Insulin Pumps PA program.
 This change applies to the 2021 HIM, 2022 HIM, Balanced, Performance and Performance Select Drug Lists.\*

## **New Programs Added to Select Drug Lists**

- Effective Sept. 1, 2022, the Interleukin-13 (IL-13) Antagonist Specialty PA program and target drug Adbry (tralokinumab-ldrm) will be added to the 2021 HIM, 2022 HIM, Balanced, Performance and Performance Select Drug Lists.\*
- Effective Oct. 1, 2022, the following changes will be applied:
  - The Cibinqo Specialty PA program and target drug Cibinqo will be added to the 2021
     HIM, 2022 HIM, Balanced, Performance and Performance Select Drug Lists.\*
  - The Pyrukynd Specialty PA program and target drug Pyrukynd (mitapivat) will be added to the 2021 HIM, 2022 HIM, Balanced, Performance and Performance Select Drug Lists.\*
  - The Recorlev Specialty PA program and target drug Recorlev (levoketoconazole) will be added to the 2021 HIM, 2022 HIM, Balanced, Performance and Performance Select Drug Lists.\*
  - The Tarpeyo PA program and target drug TARPEYO (budesonide) will be added to the 2021 HIM, 2022 HIM, Balanced, Performance and Performance Select Drug Lists.\*

**Please Note:** As a reminder, the PA programs for standard pharmacy benefit plans correlate to a member's drug list. Not all standard PA programs may apply, based on the member's current drug list. A list of PA programs per drug list is posted on the member pharmacy and prescription plan information section of bcbsok.com.

Members were notified about the PA standard program changes listed in the tables below.

Drug categories added to current pharmacy PA standard programs, effective July 1, 2022:

Drug Category	Targeted Medication(s) <sup>1</sup>
Basic and Enhanced Drug Lists	
Cibinqo	Cibinqo (abrocitinib) <sup>2*</sup>
IL-13 Antagonist	Adbry (tralokinumab-ldrm) <sup>2*</sup>

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner.

<sup>\*</sup> Not all members may have been notified due to limited utilization.

<sup>&</sup>lt;sup>2</sup> Member level PAs were entered through Oct. 1, 2022, for Basic and Enhanced Drug Lists.

<sup>\*</sup> Not all members may have been notified due to limited utilization.

# Drug categories added to current pharmacy PA standard programs, effective Oct. 1, 2022:

Drug Category	Targeted Medication(s) <sup>1</sup>	
Basic and Enhanced Drug Lists		
Pyrukynd	Pyrukynd (mitapivat) Therapy Pack 5 MG*, Pyrukynd (mitapivat) Therapy Pack 7 x 20 MG & 7 x 5 MG*, Pyrukynd (mitapivat) Therapy Pack 7 x 50 MG & 7 x 20 MG*, Pyrukynd (mitapivat) 5 mg tablets*, Pyrukynd (mitapivat) 20 mg tablets*, Pyrukynd (mitapivat) 50 mg tablets*	
Recorlev	Recorlev (levoketoconazole)*	
Tarpeyo	TARPEYO (budesonide)*	

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner.

# Targeted drugs added to current pharmacy PA standard programs, effective Oct. 1, 2022:

Drug Category	Targeted Medication(s) <sup>1</sup>	
Basic, Enhanced and Balanced Drug Lists		
Alternative Dosage Form  Dartisla ODT*, Lyvispah (baclofen) 5 mg Granule packet*, Lyvispah (baclofen) 10 mg Granule packet*, Lyvispah (baclofen) 20 mg Granule packet*, Valsartan oral solu		
Basic, Enhanced, 2021 Health Insurance Marketplace (HIM) and 2022 HIM Drug Lists		
Insulin Pumps	Omnipod DASH kit/Omnipod 5 kit*	
Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists		
Therapeutic Alternatives	METAXALONE TAB 400 MG*, METFORMIN TAB 625 M PHOSPHOLINE SOL 0.125% OP*, PREDNISOLONE SO PHOSPHATE ORAL SOLN 10 MG/5 ML (BASE EQUIV) VTAMA (tapinarof) 1% CREAM*	

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner.

\* Not all members may have been notified due to limited utilization.

Targeted mailings were sent to members affected by drug list revisions and/or exclusions and prior authorization program changes per our usual process of notifying members prior to the effective date.

View the most up-to-date drug list and list of drug dispensing limits on bcbsok.com.

# **Change in Benefit Coverage for Select High Cost Products**

Several high cost products with available lower cost alternatives will be excluded on the pharmacy benefit for select drug lists. This change impacts BCBSOK members who have prescription drug benefits administered by Prime Therapeutics. This change is part of an ongoing effort to make sure our members and employer groups have access to safe, cost-effective medications.

<sup>\*</sup> Not all members may have been notified due to limited utilization.

High cost products that either are new to market or have therapeutic equivalents available have also been excluded. Please note: Members were not notified of these changes because there is no utilization or the pharmacist can easily fill a member's prescription with the equivalent without needing a new prescription from the doctor. The following drugs are excluded on select drug lists:

Product(s) No Longer Covered <sup>1*</sup>	Condition Used For	Covered Alternative(s) <sup>1,2</sup>
DICLOFENAC TAB 25 MG	PAIN	DICLOFENAC POT 50 MG, MELOXICAM, IBUPROFEN, NAPROXEN
METFORMIN TAB 625 MG	DIABETES	METFORMIN 500 MG TABS
ORPHENADRINE W/ ASPIRIN & CAFFEINE TAB 25-385-30 MG	MUSCLE PAIN	CYCLOBENZAPRINE, ORPHENADRINE

<sup>1</sup> All brand names are the property of their respective owners.

## Updates to the Member Pay the Difference (MPTD) Program

What's new: In 2023, some operational changes will be made to the MPTD program in efforts to standardize the program and help drive generic utilization.

Background: MPTD requires members who fill a brand name prescription, for which there is an exact generic equivalent, to pay the applicable copay or coinsurance plus the difference in cost between the brand and generic drug. Currently, the MPTD program is being managed differently depending on the line of business, the prescription drug list and state/plan.

Member notices: Impacted members will receive a letter at least 60 days prior to the effective date.

If you have any questions regarding these changes, contact your BCBSOK representative.

## **Split Fill Program Category Expansion**

2023 change: The Split Fill Program will be expanded to include additional categories beyond oral oncology medications, such as multiple sclerosis and iron toxicity.

Background: The Split Fill Program provides a partial, or "split" fill, of a member's monthly prescription for select medications for up to three months of therapy. This helps minimize waste and reduces health plan costs by identifying drugs associated with early discontinuation or dose modifications.

Reminder: There are no changes as to how the Split Fill Program works. Groups cannot pick and choose the categories that will now apply.

If you have any questions regarding these changes, contact your BCBSOK representative.

<sup>2</sup> This list is not all-inclusive. Other products may be available.

\* This chart applies to members on the Basic, Multi-Tier Basic, Enhanced and Multi-Tier Enhanced Drug Lists.

# **BCBSOK Change for Maintenance Indicator**

**Benefit update:** Maintenance and non-maintenance medications for BCBSOK members will be available for up to a 90-day supply.

**Learn more:** Currently, only maintenance medications are available for up to a 90-day supply. This change will align with other states and allow for an improved member experience.

If you have any questions regarding these changes, contact your BCBSOK representative.

# **BCBSOK Increase in Mail Order Multiplier**

**New:** Starting Jan. 1, 2023, upon renewal, BCBSOK members' cost share for 90-day supplies filled at extended network supply retail pharmacies and/or mail order/home delivery pharmacies will increase from 2.5x to 3x the cost of a 30-day supply.

If you have any questions regarding these changes, contact your BCBSOK representative.

BCBSOK contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSOK, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics. MyPrime.com is an online resource offered by Prime Therapeutics.